• Home
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Jacinta Flattery O’Brien PhD
    • Jennifer Enmon PhD JD
    • Grant Shoebridge PhD
    • Kadri Elcoat
    • Kate Legge
    • Lesley White
    • Alex May
    • Christopher Coates
    • Jessica Chadbourne PhD
    • Joanne Grant
    • Emily Bristow
    • Brittany Deleon
    • Ana Maria Chaves
    • Erni Othman
    • Amber Cross
  • News
    • Pearce IP Blog
    • BioBlast™
  • Blog
  • BioBlast™
  • Contact Us

Home / News / BioBlast™

Aurobindo Pharma announces CuraTeQ Biologics intention to file biosimilar applications

Aug 5, 2020

In its Q4 FY20 earnings call, Aurobindo Pharma announced that its wholly owned subsidiary CuraTeQ Biologics intends to file applications for two of its biosimilar products in EU at the end of 2020 or start of 2021, with target EU launches following one year later. Aurobindo also announced further biosimilar products are expected to enter Ph III trials in early 2021.

View all BioBlast™ Updates

Product specific reports based on extracts from our BioBlast™ database

adalimumab | Humira® | AbbVie

aflibercept | Eylea® | Regeneron

bevacizumab | Avastin® | Roche/Genentech

cetuximab | Erbitux® | BMS/Merck

darbepoetin | Aranesp® | Amgen

denosumab | Prolia®/Xgeva® | Amgen

eculizumab | Soliris® | Alexion

etanercept | Enbrel® | Amgen

filgrastim (GCSF) | Neupogen® | Amgen

golimumab | Simponi® | Janssen

infliximab | Remicade® | Johnson & Johnson

natalizumab | Tysabri® | Biogen/Elan

omalizumab | Xolair® | Genentech / Novartis

pegfilgrastim | Neulasta® | Amgen

pembrolizumab | Keytruda® | Merck

pertuzumab | Perjeta® | Roche

ranibizumab | Lucentis® | Genentech

rituximab | Rituxan®/MabThera® | Genentech/Biogen

tocilizumab | Actemra® | Roche

trastuzumab | Herceptin® | Roche/Genentech

ustekinumab | Stelara® | Johnson & Johnson

View latest BioBlast™ updates

Biosimilars Deals

2020 Deals

2019 Deals

2018 Deals

SUBSCRIBE TO PEARCE IP

Sign up to our latest news

Receive our Pearce IP Blog and weekly BioBlast™ via email.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast™
  • Contact Us
  • Follow

Copyright © 2021 Pearce IP. All Rights Reserved.

Contact Us

Email: info@pearceIP.law
Tel: +61 (0) 2 9023 9988

For any general inquiries, please fill in the following contact form:

 





    Subscribe to our BioBlast™

    Fill in the form below to recieve our BioBlast™ Updates, Pearce IP Blog and other relevant industry updates.

     



      What emails do you want to receive?